Showing results (261-270 of 397) with videos related to

Sort By:
Pageof 40
Gynecologic Oncology|September 19, 1998
Phase 2 trial of single agent ifosfamide/mesna in patients with platinum/paclitaxel refractory ovarian cancer who have not previously been treated with an alkylating agentM Markman, A Kennedy, G Sutton, et al.
JACC. Clinical Electrophysiology|October 4, 2024
Augmentation of Atrial Conduction Velocity With Pharmacological and Direct Electrical Sympathetic StimulationTimothy M Markman, Lingyu Xu, Sohail Zahid, et al.
Gynecologic Oncology|September 30, 1999
Intraperitoneal interferon-alpha in residual ovarian carcinoma: a phase II gynecologic oncology group studyJ S Berek, M Markman, B Stonebraker, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|June 29, 2006
Surgery alone or surgery with a combination radiation or chemoradiation for management of patients with bulky-stage IB2 cervical carcinomaJ P Micha, B H Goldstein, M A Rettenmaier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1991
Phase II trial of weekly or biweekly intraperitoneal mitoxantrone in epithelial ovarian cancerM Markman, T Hakes, B Reichman, et al.
Applied Clinical Informatics|July 23, 2013
Medical student appraisal: applications for bedside patient educationT M Markman, P J Sampognaro, S L Mitchell, et al.
The Yale Journal of Biology and Medicine|July 1, 1989
Intraperitoneal therapy in the management of ovarian carcinomaM Markman, T Hakes, B Reichman, et al.
American Journal of Obstetrics and Gynecology|November 1, 1988
Recurrence after negative second-look laparotomy for ovarian cancer: analysis of risk factorsS C Rubin, W J Hoskins, T B Hakes, et al.
Gynecologic Oncology|December 6, 2001
BRCA1 germline mutations and polymorphisms in a clinic-based series of ovarian cancer cases: a Gynecologic Oncology Group studyS A Smith, W E Richards, K Caito, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 11, 1991
Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatinM Markman, B Reichman, T Hakes, et al.
Pageof 40